Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme
Jiemiao Hu, Qingnan Zhao, Ling-Yuan Kong, Jian Wang, Jun Yan, Xueqing Xia, Zhiliang Jia, Amy B. Heimberger, Shulin Li
Abstract
T cell accumulation in vitro and in vivo. CXCL1/2 also promoted the paracrine factor S100A9 and further activated Erk1/2 and p70S60k, whereas blocking CXCL1/2 down-regulated these prosurvival factors. The combination of targeting CXCL1/2 and standard temozolomide chemotherapy improved upon the antitumor efficacy of chemotherapy alone, extending the overall survival time in GBM.
Topics & Concepts
GlioblastomaImmune systemCancer researchCancerMedicineCXCL1OncologyBiologyInternal medicineImmunologyChemokineChemokine receptors and signalingImmune cells in cancerinterferon and immune responses